Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
2.040
+0.070 (3.55%)
At close: Oct 21, 2025, 4:00 PM EDT
2.010
-0.030 (-1.47%)
After-hours: Oct 21, 2025, 7:59 PM EDT
Invivyd Revenue
Invivyd had revenue of $11.79M in the quarter ending June 30, 2025, with 420.58% growth. This brings the company's revenue in the last twelve months to $46.21M, up 1,941.08% year-over-year. In the year 2024, Invivyd had annual revenue of $25.38M.
Revenue (ttm)
$46.21M
Revenue Growth
+1,941.08%
P/S Ratio
5.29
Revenue / Employee
$462,100
Employees
100
Market Cap
437.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25.38M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
IVVD News
- 15 days ago - Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID - GlobeNewsWire
- 27 days ago - Invivyd Appoints Paul B. Bolno, M.D. - GlobeNewsWire
- 4 weeks ago - Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer - GlobeNewsWire
- 6 weeks ago - SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025 - GlobeNewsWire
- 7 weeks ago - Invivyd: Superior COVID Prophylaxis; Eventual Winner Regardless Of Trump Admin Anti-Vaccine Actions - Seeking Alpha
- 7 weeks ago - Invivyd to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares - GlobeNewsWire
- 2 months ago - Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire